# Nicotine

## Nicotinell TTS 30

| TAH Drug Code      | [ENIC3](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ENIC3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | To aid smoking cessation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Dosing             | (Uptodate) Nicotinell TTS 10: 10 cm2 (7 mg/day); TTS 20: 20 cm2 (14 mg/day); TTS 30: 30 cm2 (21 mg/day). Transdermal patch: Adjustment may be required during initial treatment (move to higher dose if experiencing withdrawal symptoms; lower dose if side effects are experienced). Patients smoking > 10 cigarettes/day: Begin with step 1 (21 mg/day) for 6 weeks, followed by step 2 (14 mg/day) for 2 weeks; finish with step 3 (7 mg/day) for 2 weeks. Patients smoking ? 10 cigarettes/day: Begin with step 2 (14 mg/day) for 6 weeks, followed by step 3 (7 mg/day) for 2 weeks. Do not exceed more than 3 months of treatment. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Contraindications  | Non-smokers, children & occasional smokers. Acute MI, unstable or worsening angina pectoris, severe cardiac arrhythmias, recent CVA, skin diseases. Pregnancy, lactation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Adverse Effects    | Most frequent: Reaction at application site (usually erythema or pruritus), headache, cold & flu-like symptoms, insomnia, nausea, myalgia & dizziness. Less common: BP changes, other CNS effects & GI disturbances. Also see lit.                                                                                                                                                                                                                                                                                                                                                                                                        |
| Pregnancy          | Compatible – Maternal Benefit >> Embryo-Fetal Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

## Smokquit 2mg (24 tablets/box)

| TAH Drug Code      | [OSQL2](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OSQL2)                                                                                                                                                                                                                                                                                                                                                   |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Smoking Cessation Aid                                                                                                                                                                                                                                                                                                                                                                                                    |
| Dosing             | Patients who smoke their first cigarette within 30 minutes of waking should use the 4 mg strength; otherwise the 2 mg strength is recommended. Use according to the following 12-week dosing schedule: Weeks 1 to 6: 1 lozenge every 1 to 2 hours, use at least 9 lozenges/day. Weeks 7 to 9: 1 lozenge every 2 to 4 hours. Weeks 10 to 12: 1 lozenge every 4 to 8 hours. The recommended maximum dose: 15 lozenges/day. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                            |
| Contraindications  | Hypersensitivity to nicotine or any component of the product.                                                                                                                                                                                                                                                                                                                                                            |
| Adverse Effects    | Common Dermatologic: Skin irritation, Patch Respiratory: Nasal irritation, Nasal spray, Oral irritation, Airway, inhaler Other: Nicotine withdrawal, Dizziness, headache, insomnia Serious Cardiovascular: Cardiac dysrhythmia (rare), Hypertension (rare), Tachyarrhythmia (rare) Immunologic: Hypersensitivity reaction (rare)                                                                                         |
| Pregnancy          | Compatible – Maternal Benefit >> Embryo-Fetal Risk                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                             |

## SMOKQUIT 4mg (24 tablets/box)

| TAH Drug Code      | [OSQL4](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OSQL4)                                                                                                                                                                                                                                                                                                                                                   |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Smoking Cessation Aid.                                                                                                                                                                                                                                                                                                                                                                                                   |
| Dosing             | Patients who smoke their first cigarette within 30 minutes of waking should use the 4 mg strength; otherwise the 2 mg strength is recommended. Use according to the following 12-week dosing schedule: Weeks 1 to 6: 1 lozenge every 1 to 2 hours, use at least 9 lozenges/day. Weeks 7 to 9: 1 lozenge every 2 to 4 hours. Weeks 10 to 12: 1 lozenge every 4 to 8 hours. The recommended maximum dose: 15 lozenges/day. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                            |
| Contraindications  | Hypersensitivity to nicotine or any component of the product.                                                                                                                                                                                                                                                                                                                                                            |
| Adverse Effects    | Common Dermatologic: Skin irritation, Patch Respiratory: Nasal irritation, Nasal spray, Oral irritation, Airway, inhaler Other: Nicotine withdrawal, Dizziness, headache, insomnia Serious Cardiovascular: Cardiac dysrhythmia (rare), Hypertension (rare), Tachyarrhythmia (rare) Immunologic: Hypersensitivity reaction (rare)                                                                                         |
| Pregnancy          | Compatible – Maternal Benefit >> Embryo-Fetal Risk                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                             |

